These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 33241139)
1. Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells. Uddin MH; Kim B; Cho U; Azmi AS; Song YS Heliyon; 2020 Nov; 6(11):e05442. PubMed ID: 33241139 [TBL] [Abstract][Full Text] [Related]
2. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP). Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816 [TBL] [Abstract][Full Text] [Related]
3. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Song K; Li Z; Seth P; Cowan KH; Sinha BK Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines]. Cheng G; Li Y; Tian F Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113 [TBL] [Abstract][Full Text] [Related]
5. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling. Kim D; Choi BH; Ryoo IG; Kwak MK Cell Death Dis; 2018 Aug; 9(9):896. PubMed ID: 30166520 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer. Zou W; Ma X; Yang H; Hua W; Chen B; Cai G Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551 [TBL] [Abstract][Full Text] [Related]
7. Hedgehog-Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1. Wang Q; Wei X; Hu L; Zhuang L; Zhang H; Chen Q Front Oncol; 2021; 11():794959. PubMed ID: 35059317 [TBL] [Abstract][Full Text] [Related]
8. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway. Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines. Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528 [TBL] [Abstract][Full Text] [Related]
10. Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway. Wei X; Shi J; Lin Q; Ma X; Pang Y; Mao H; Li R; Lu W; Wang Y; Liu P Front Oncol; 2021; 11():642229. PubMed ID: 33816292 [No Abstract] [Full Text] [Related]
11. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949 [TBL] [Abstract][Full Text] [Related]
12. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Solár P; Sytkowski AJ Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Vikhanskaya F; Clerico L; Valenti M; Stanzione MS; Broggini M; Parodi S; Russo P Int J Cancer; 1997 Jul; 72(1):155-9. PubMed ID: 9212237 [TBL] [Abstract][Full Text] [Related]
14. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260 [TBL] [Abstract][Full Text] [Related]
15. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Cai J; Yang C; Yang Q; Ding H; Jia J; Guo J; Wang J; Wang Z Oncogenesis; 2013 Oct; 2(10):e75. PubMed ID: 24100610 [TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways]. Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551 [TBL] [Abstract][Full Text] [Related]
17. Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. Jendželovská Z; Jendželovský R; Hiľovská L; Kovaľ J; Mikeš J; Fedoročko P Toxicol In Vitro; 2014 Oct; 28(7):1259-73. PubMed ID: 24994473 [TBL] [Abstract][Full Text] [Related]
18. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Yan XD; Li M; Yuan Y; Mao N; Pan LY Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060 [TBL] [Abstract][Full Text] [Related]
19. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells. Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949 [TBL] [Abstract][Full Text] [Related]
20. Resistance Improvement and Sensitivity Enhancement of Cancer Therapy by a Novel Antitumor Candidate onto A2780 CP and A2780 S Cell Lines. Mohammadi Hadloo S; Mohseni Kouchesfahani H; Khanlarkhani A; Saeidifar M Rep Biochem Mol Biol; 2023 Oct; 12(3):374-385. PubMed ID: 38618266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]